Vedolizumab

Vedolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	Integrin α4β7
Clinical data
Trade names	Entyvio
AHFS/Drugs.com	Monograph
MedlinePlus	a614034
License data	US DailyMed: Vedolizumab;
Pregnancy; category	AU: B2;
Routes of; administration	Intravenous
ATC code	L04AG05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	943609-66-3 ;
DrugBank	DB09033 ;
ChemSpider	none;
UNII	9RV78Q2002;
KEGG	D08083;
Chemical and physical data
Formula	C6528H10072N1732O2042S42
Molar mass	146836.99 g·mol−1
	(what is this?) (verify)

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇ (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity.